[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]

Area of Science:

• Oncology
• Genetics
• Pulmonology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard for EGFR-mutated adenocarcinomas.
• Limited data exists on EGFR-mutated non-adenocarcinomas in clinical trials.
• Efficacy and clinicopathological correlations of TKIs in non-adenocarcinomas are debated.

Purpose of the Study:

• To evaluate the efficacy of EGFR TKIs in EGFR-mutated non-adenocarcinomas.
• To explore the relationship between clinicopathological characteristics and TKI treatment outcomes.
• To assess the role of TKIs in non-adenocarcinoma non-small cell lung cancer (NSCLC).

Main Methods:

• Retrospective analysis of EGFR mutation frequency and TKI treatment efficacy.
• Comparison of outcomes between adenocarcinoma and non-adenocarcinoma subtypes.
• Investigation of smoking status and histology (adenosquamous, squamous cell, large cell) as factors influencing TKI efficacy.

Main Results:

• EGFR mutation rates are lower in non-adenocarcinomas than adenocarcinomas.
• TKI efficacy appears inferior in non-adenocarcinomas compared to adenocarcinomas.
• Smoking status significantly impacts TKI efficacy in EGFR-mutated non-adenocarcinomas.
• Adenosquamous cell carcinoma shows higher EGFR mutation rates and TKI efficacy than squamous cell or large cell carcinoma.

Conclusions:

• EGFR mutations are not rare in non-adenocarcinoma NSCLC in mainland China.
• EGFR TKIs may be a viable treatment option for EGFR-mutated non-adenocarcinoma NSCLC, especially for adenosquamous histology and non-smokers.
• Large-scale prospective studies are essential to fully understand non-adenocarcinoma characteristics and optimize TKI or chemotherapy treatment strategies.